Physician profile
Rokshana Sharifa
NPI 1760476089
$1,625.55
in general payments reported to CMS, 2019-2025
22 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $244 · 2021: $343 · 2024: $629 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $261.08 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $258.06 | 2021-2025 | |
| Glaxosmithkline, LLC. | $187.94 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $165.96 | 2019-2021 | |
| Pfizer INC. | $154.75 | 2019-2021 | |
| Lilly USA, LLC | $140.55 | 2024-2025 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.51 | 2021-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $50.61 | 2019-2024 | Airsupra |
| Astellas Pharma US INC | $42.18 | 2019-2024 | Veozah |
| Abbott Laboratories | $41.78 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $38.76 | 2024 | Repatha, Otezla |
| Boston Scientific Corporation | $29.20 | 2020 | |
| Allergan, INC. | $27.77 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $23.04 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.17 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $18.17 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.50 | 2024 | Quviviq |
| Dexcom, INC. | $16.07 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $15.86 | 2019 | |
| Eisai INC. | $15.40 | 2020 | |
| Esperion Therapeutics, INC. | $12.25 | 2021 | |
| Seqirus USA INC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rokshana Sharifa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.